BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10506718)

  • 1. Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma.
    Sato S; Kigawa J; Minagawa Y; Okada M; Shimada M; Takahashi M; Kamazawa S; Terakawa N
    Cancer; 1999 Oct; 86(7):1307-13. PubMed ID: 10506718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
    Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
    Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of p53 protein and the apoptotic regulatory molecules Bcl-2, Bcl-XL, and Bax in locally advanced squamous cell carcinoma of the lung.
    Shabnam MS; Srinivasan R; Wali A; Majumdar S; Joshi K; Behera D
    Lung Cancer; 2004 Aug; 45(2):181-8. PubMed ID: 15246189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
    Andrews GA; Xi S; Pomerantz RG; Lin CJ; Gooding WE; Wentzel AL; Wu L; Sidransky D; Grandis JR
    Head Neck; 2004 Oct; 26(10):870-7. PubMed ID: 15390206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy for epithelial ovarian cancer--role of apoptosis.
    Dutta T; Sharma H; Kumar L; Dinda AK; Kumar S; Bhatla N; Singh N
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):427-35. PubMed ID: 15906030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells.
    Chang FL; Lai MD
    J Urol; 2001 Jul; 166(1):304-10. PubMed ID: 11435891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 gene status and chemosensitivity in ovarian cancer.
    Kigawa J; Sato S; Shimada M; Takahashi M; Itamochi H; Kanamori Y; Terakawa N
    Hum Cell; 2001 Sep; 14(3):165-71. PubMed ID: 11774736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
    Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F
    Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol.
    Silvestrini R; Daidone MG; Veneroni S; Benini E; Scarfone G; Zanaboni F; Villa A; Presti M; Danese S; Bolis G
    Cancer; 1998 Jan; 82(1):159-67. PubMed ID: 9428493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced ING1b gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients.
    Kameyama K; Huang CL; Liu D; Masuya D; Nakashima T; Sumitomo S; Takami Y; Kinoshita M; Yokomise H
    Clin Cancer Res; 2003 Oct; 9(13):4926-34. PubMed ID: 14581367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptotic index in ovarian carcinoma: correlation with clinicopathologic factors and prognosis.
    Yamasaki F; Tokunaga O; Sugimori H
    Gynecol Oncol; 1997 Sep; 66(3):439-48. PubMed ID: 9299259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 mutation is infrequent in clear cell carcinoma of the ovary.
    Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
    Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of p53 in G2/M cell cycle arrest and apoptosis in response to gamma-irradiation in ovarian carcinoma cell lines.
    Concin N; Stimpfl M; Zeillinger C; Wolff U; Hefler L; Sedlak J; Leodolter S; Zeillinger R
    Int J Oncol; 2003 Jan; 22(1):51-7. PubMed ID: 12469184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous apoptosis in ovarian carcinomas: a positive association with p53 gene mutation is dependent on growth fraction.
    Kupryjańczyk J; Dansonka-Mieszkowska A; Szymańska T; Karpińska G; Rembiszewska A; Rusin M; Konopiński R; Kraszewska E; Timorek A; Yandell DW; Stelmachów J
    Br J Cancer; 2000 Feb; 82(3):579-83. PubMed ID: 10682669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferative activity and apoptosis in thymic epithelial neoplasms.
    Hiroshima K; Iyoda A; Toyozaki T; Supriatna Y; Shibuya K; Shimamura F; Haga Y; Yoshida S; Fujisawa T; Ohwada H
    Mod Pathol; 2002 Dec; 15(12):1326-32. PubMed ID: 12481014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis, PCNA and p53 in hepatocellular carcinoma.
    Paiva C; Oshima CT; Lanzoni VP; Forones NM
    Hepatogastroenterology; 2002; 49(46):1058-61. PubMed ID: 12143201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer.
    Ramondetta L; Mills GB; Burke TW; Wolf JK
    Clin Cancer Res; 2000 Jan; 6(1):278-84. PubMed ID: 10656459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis in epithelial ovarian tumours Prognostic significance of clinical and histopathologic factors and its association with the immunohistochemical expression of apoptotic regulatory proteins (p53, bcl-2 and bax).
    de la Torre FJ; García A; Gil-Moreno A; Planaguma J; Reventos J; Ramón y Cajal S; Xercavins J
    Eur J Obstet Gynecol Reprod Biol; 2007 Jan; 130(1):121-8. PubMed ID: 16876311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pro-apoptotic treatment with an adenovirus encoding Bax enhances the effect of chemotherapy in ovarian cancer.
    Xiang J; Gómez-Navarro J; Arafat W; Liu B; Barker SD; Alvarez RD; Siegal GP; Curiel DT
    J Gene Med; 2000; 2(2):97-106. PubMed ID: 10809143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
    Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
    Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.